SG11201700956VA - Indoles for use in influenza virus infection - Google Patents
Indoles for use in influenza virus infectionInfo
- Publication number
- SG11201700956VA SG11201700956VA SG11201700956VA SG11201700956VA SG11201700956VA SG 11201700956V A SG11201700956V A SG 11201700956VA SG 11201700956V A SG11201700956V A SG 11201700956VA SG 11201700956V A SG11201700956V A SG 11201700956VA SG 11201700956V A SG11201700956V A SG 11201700956VA
- Authority
- SG
- Singapore
- Prior art keywords
- indoles
- influenza virus
- virus infection
- infection
- influenza
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Virology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Pulmonology (AREA)
- Engineering & Computer Science (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP14180331 | 2014-08-08 | ||
PCT/EP2015/068257 WO2016020526A1 (en) | 2014-08-08 | 2015-08-07 | Indoles for use in influenza virus infection |
Publications (1)
Publication Number | Publication Date |
---|---|
SG11201700956VA true SG11201700956VA (en) | 2017-03-30 |
Family
ID=51298610
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11201700956VA SG11201700956VA (en) | 2014-08-08 | 2015-08-07 | Indoles for use in influenza virus infection |
Country Status (18)
Country | Link |
---|---|
US (1) | US10597390B2 (en) |
EP (1) | EP3177609A1 (en) |
JP (1) | JP6577570B2 (en) |
KR (1) | KR102488479B1 (en) |
CN (1) | CN106573920B (en) |
AU (1) | AU2015298876B2 (en) |
BR (1) | BR112017002370B1 (en) |
CA (1) | CA2954751C (en) |
CL (1) | CL2017000309A1 (en) |
EA (1) | EA201790266A1 (en) |
IL (1) | IL250408B (en) |
MA (1) | MA40547A (en) |
MX (1) | MX2017001752A (en) |
PH (1) | PH12017500207B1 (en) |
SG (1) | SG11201700956VA (en) |
UA (1) | UA124609C2 (en) |
WO (1) | WO2016020526A1 (en) |
ZA (1) | ZA201700952B (en) |
Families Citing this family (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GEP20156325B (en) | 2009-06-17 | 2015-07-10 | Vertex Pharma | Inhibitors of influenza viruses replication |
UA118010C2 (en) | 2011-08-01 | 2018-11-12 | Вертекс Фармасьютікалз Інкорпорейтед | INFLUENCES OF INFLUENZA VIRUS REPLICATION |
EA201790266A1 (en) | 2014-08-08 | 2017-06-30 | Янссен Сайенсиз Айрлэнд Юси | INDOLS FOR USE IN INFECTIONS CAUSED BY THE FLU VIRUS |
WO2016183116A1 (en) | 2015-05-13 | 2016-11-17 | Vertex Pharmaceuticals Incorporated | Methods of preparing inhibitors of influenza viruses replication |
WO2016183120A1 (en) | 2015-05-13 | 2016-11-17 | Vertex Pharmaceuticals Incorporated | Inhibitors of influenza viruses replication |
AU2016368317B2 (en) | 2015-12-09 | 2019-05-23 | Sunshine Lake Pharma Co., Ltd. | Inhibitors of influenza virus replication, application methods and uses thereof |
LT3400225T (en) * | 2016-01-07 | 2021-12-10 | Janssen Sciences Ireland Unlimited Company | Pentanoic acids substituted by pyrrolo-[2-3,b]pyrimidine-pyridines for the treatment of influenza viral infections |
WO2017133670A1 (en) * | 2016-02-05 | 2017-08-10 | Savira Pharmaceuticals Gmbh | Pyridine and pyrimidine derivatives and their use in treatment, amelioration or prevention of influenza |
CN107759571B (en) * | 2016-08-16 | 2021-03-02 | 广东东阳光药业有限公司 | Inhibitors of influenza virus replication and methods of use and uses thereof |
CN109641868B (en) * | 2016-08-30 | 2021-12-03 | 广东东阳光药业有限公司 | Inhibitors of influenza virus replication and methods of use and uses thereof |
RU2727772C1 (en) | 2016-09-05 | 2020-07-23 | Гуандун Рэйновент Байотек Ко., Лтд. | Pyrimidine derivatives against influenza virus |
AU2017376541B2 (en) | 2016-12-15 | 2021-08-05 | Sunshine Lake Pharma Co., Ltd. | Inhibitors of influenza virus replication and uses thereof |
JP7299837B2 (en) | 2016-12-23 | 2023-06-28 | アクイナ ファーマシューティカルズ, インコーポレイテッド | Compounds, compositions and methods of use |
WO2018127096A1 (en) | 2017-01-05 | 2018-07-12 | Sunshine Lake Pharma Co., Ltd. | Inhibitors of influenza virus replication and uses thereof |
WO2018157830A1 (en) | 2017-03-02 | 2018-09-07 | Sunshine Lake Pharma Co., Ltd. | Inhibitors of influenza virus replication and uses thereof |
CN108727369B (en) * | 2017-04-25 | 2023-06-09 | 广东东阳光药业有限公司 | Influenza virus replication inhibitors and uses thereof |
KR102484804B1 (en) | 2018-03-05 | 2023-01-04 | 광둥 레이노벤트 바이오테크 컴퍼니 리미티드 | Crystal form and salt form of imidazole-based compound and method for preparing the same |
EP3992192A4 (en) * | 2019-07-22 | 2022-08-17 | Guangdong Raynovent Biotech Co., Ltd. | Dominant salt forms of pyrimidine derivatives, and crystal forms thereof |
CN113045475A (en) * | 2019-12-27 | 2021-06-29 | 上海泓博智源医药股份有限公司 | Preparation method of 5-bromo-7-methylindole |
AU2021313150A1 (en) * | 2020-07-20 | 2023-03-16 | Nido Biosciences, Inc. | Indole compounds as androgen receptor modulators |
WO2024081748A2 (en) * | 2022-10-12 | 2024-04-18 | Maze Therapeutics, Inc. | Inhibitors of solute carrier family 6a member 19 (slc6a19) and methods of use thereof |
Family Cites Families (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ATE508129T1 (en) | 2004-03-30 | 2011-05-15 | Vertex Pharma | AZAINDOLS SUITABLE AS INHIBITORS OF JAK AND OTHER PROTEIN KINASES |
BRPI0722364A2 (en) | 2006-01-17 | 2011-08-16 | Vertex Pharma | azaindoles, pharmaceutical composition and uses of said compounds |
GEP20156325B (en) | 2009-06-17 | 2015-07-10 | Vertex Pharma | Inhibitors of influenza viruses replication |
JP5876051B2 (en) * | 2010-09-08 | 2016-03-02 | グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドGlaxosmithkline Intellectual Property Development Limited | Indazole derivatives for use in the treatment of influenza virus infection |
MX2013006836A (en) | 2010-12-16 | 2013-09-26 | Vertex Pharma | Inhibitors of influenza viruses replication. |
EP2651938A1 (en) * | 2010-12-16 | 2013-10-23 | Vertex Pharmaceuticals Incorporated | Inhibitors of influenza viruses replication |
UA118010C2 (en) * | 2011-08-01 | 2018-11-12 | Вертекс Фармасьютікалз Інкорпорейтед | INFLUENCES OF INFLUENZA VIRUS REPLICATION |
JP6096778B2 (en) | 2011-09-01 | 2017-03-15 | エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト | Pyrrolopyrazine kinase inhibitor |
WO2013184985A1 (en) | 2012-06-08 | 2013-12-12 | Vertex Pharmaceuticals Incorporated | Inhibitors of influenza viruses replication |
RS59144B1 (en) | 2013-11-13 | 2019-09-30 | Vertex Pharma | Inhibitors of influenza viruses replication |
UY36255A (en) | 2014-08-08 | 2016-01-29 | Bayer Cropscience Ag | SUBSTITUTED COMPOUNDS BY HALOGEN NOVEDOSOS |
AR101401A1 (en) | 2014-08-08 | 2016-12-14 | Bayer Cropscience Ag | BIPIRAZOL DERIVATIVES, REPLACED WITH HALOGEN |
EA201790266A1 (en) | 2014-08-08 | 2017-06-30 | Янссен Сайенсиз Айрлэнд Юси | INDOLS FOR USE IN INFECTIONS CAUSED BY THE FLU VIRUS |
CN104592038A (en) | 2015-01-12 | 2015-05-06 | 烟台万润精细化工股份有限公司 | Preparation method of 5,5-dimethyl-1,3-cyclohexamethylenediamine |
-
2015
- 2015-08-07 EA EA201790266A patent/EA201790266A1/en unknown
- 2015-08-07 UA UAA201702154A patent/UA124609C2/en unknown
- 2015-08-07 MX MX2017001752A patent/MX2017001752A/en unknown
- 2015-08-07 KR KR1020177005979A patent/KR102488479B1/en active IP Right Grant
- 2015-08-07 EP EP15750365.7A patent/EP3177609A1/en not_active Withdrawn
- 2015-08-07 CA CA2954751A patent/CA2954751C/en active Active
- 2015-08-07 BR BR112017002370-9A patent/BR112017002370B1/en not_active IP Right Cessation
- 2015-08-07 MA MA040547A patent/MA40547A/en unknown
- 2015-08-07 WO PCT/EP2015/068257 patent/WO2016020526A1/en active Application Filing
- 2015-08-07 CN CN201580042406.9A patent/CN106573920B/en active Active
- 2015-08-07 AU AU2015298876A patent/AU2015298876B2/en not_active Ceased
- 2015-08-07 SG SG11201700956VA patent/SG11201700956VA/en unknown
- 2015-08-07 JP JP2017506964A patent/JP6577570B2/en not_active Expired - Fee Related
- 2015-08-07 US US15/501,730 patent/US10597390B2/en not_active Expired - Fee Related
-
2017
- 2017-02-02 IL IL250408A patent/IL250408B/en active IP Right Grant
- 2017-02-02 PH PH12017500207A patent/PH12017500207B1/en unknown
- 2017-02-07 CL CL2017000309A patent/CL2017000309A1/en unknown
- 2017-02-07 ZA ZA2017/00952A patent/ZA201700952B/en unknown
Also Published As
Publication number | Publication date |
---|---|
MA40547A (en) | 2017-06-14 |
US20170226102A1 (en) | 2017-08-10 |
WO2016020526A1 (en) | 2016-02-11 |
MX2017001752A (en) | 2018-02-08 |
EA201790266A1 (en) | 2017-06-30 |
IL250408B (en) | 2020-08-31 |
KR20170039275A (en) | 2017-04-10 |
CN106573920B (en) | 2020-11-10 |
BR112017002370B1 (en) | 2022-11-22 |
CN106573920A (en) | 2017-04-19 |
EP3177609A1 (en) | 2017-06-14 |
UA124609C2 (en) | 2021-10-20 |
PH12017500207A1 (en) | 2017-07-10 |
AU2015298876B2 (en) | 2020-02-13 |
PH12017500207B1 (en) | 2017-07-10 |
KR102488479B1 (en) | 2023-01-12 |
IL250408A0 (en) | 2017-03-30 |
AU2015298876A1 (en) | 2017-02-02 |
CL2017000309A1 (en) | 2017-08-18 |
ZA201700952B (en) | 2018-12-19 |
BR112017002370A2 (en) | 2017-12-05 |
US10597390B2 (en) | 2020-03-24 |
CA2954751C (en) | 2023-01-17 |
JP6577570B2 (en) | 2019-09-18 |
JP2017523225A (en) | 2017-08-17 |
CA2954751A1 (en) | 2016-02-11 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ZA201700952B (en) | Indoles for use in influenza virus infection | |
ZA201701643B (en) | Pyrrolopyrimidines for use in influenza virus infection | |
ZA201700165B (en) | Influenza virus vaccines and uses thereof | |
HK1246183A1 (en) | Hpv vaccines | |
GB201410971D0 (en) | Vaccine | |
GB201405834D0 (en) | Oncolytic virus | |
SI3380467T1 (en) | Heterocyclic indoles for use in influenza virus infection | |
GB201406608D0 (en) | Virus | |
SG11201610443WA (en) | Influenza virus vaccines and uses thereof | |
PL3185899T3 (en) | Improved hvt-vectored nd-ibd vaccine | |
SI3405466T1 (en) | Aryl substituted pyrimidines for use in influenza virus infection | |
SG11201701256RA (en) | Vaccine compositions against dengue virus diseases | |
HK1244506A1 (en) | Live attenuated vaccines for influenza viruses | |
IL247185B (en) | Tilapia lake virus vaccines | |
GB201419572D0 (en) | Virus | |
GB201402169D0 (en) | Viral inhibitors | |
SG11201701279VA (en) | Alkylated influenza vaccines | |
SI3188755T1 (en) | Vaccine | |
GB201417214D0 (en) | Vaccine | |
IL249705B (en) | Influenza virus vaccines and uses thereof | |
IL249704A0 (en) | Influenza virus vaccines and uses thereof | |
GB201406470D0 (en) | Virus | |
GB201403582D0 (en) | Virus | |
GB201408046D0 (en) | Virus preparations | |
GB201406628D0 (en) | Vaccine |